Protagonist Therapeutics, Inc.
PTGXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeProtagonist Therapeutics, Inc. operates as a discovery and development company in the United States. With a market capitalization of $8.96B, it sits in mid-cap territory. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
Market Cap
$8.96B
Beta
1.52
P/E (TTM)
134.40
P/E (Fwd)
-1394.62
EPS (TTM)
$1.03
EPS (Fwd)
$-0.10
ROE
11.0%
ROA
4.5%
Cash
$782.6M
Total Debt
$9.2M
Free CF
$96.1M
52W Change
84.0%
Annual Financials
Cash vs Debt
Where PTGX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PTGX finished 4.58% above its 150-day moving average ($123.11) and 13.17% above its 200-day moving average ($113.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTGX overbought or oversold?
At the October 19, 2026 close, PTGX's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $782.6M in cash and $9.2M in debt, PTGX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $96.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 11.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $26.6M (2022) to $46.0M (2025), reflecting a 73% increase over the period.
A beta of 1.52 means PTGX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, PTGX has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PTGX.